Australia Stock Alert
CLOSING UPDATE: CSL keeps rising: up 4.4% in 3 days June 20, 2018 16:00:00 AEST
NEWS BITES - AUSTRALIA
This is an end of day Alert, produced after today's Australian market close. It concludes the BSS News Bites intra-day Alert series (summaries below).
CSL, Australia's largest pharmaceuticals & biotechnology company by market capitalisation, extended its gains on Wednesday, rising an additional $A1.74 (or 0.9%) to trade at $A193.75. Trading volume was 87% of average at the end of the day. The shares have risen $A8.18 (or 4.4%) over the past three trading days vs. the All Ordinaries Index which has risen 1.1% in the same period.
Technical indicators complementing today's significant uptrend:
+ The positive 3.9 MACD (Moving Average Convergence Divergence) indicator suggests a bullish signal.
+ The stock has outperformed 89% of the Australian market over the past 6 months.
+ In the last one month the stock has hit a new 52-week high nine times and in the last three months twenty times, pointing to a significant uptrend.
+ The price lifted 2.4% in the last week and climbed 4.1% in the last month.
+ The present value of AUD1,000 invested one year ago is $A1,435 [vs $A1,083 for the All Ordinaries Index].
Fundamental measures by comparison with the sector average [in brackets] indicate:
+ Return on Equity 42.3% [19.2%]
+ Return on Assets 14.7% [8.5%]
+ Return on Capital Employed 23.7% [14.3%]
+ Year-on-Year Earnings Growth of 9.6% [8.4%]
Other Bullish Signals include:
+ Interest cover is less leveraged at 19.8 times.
+ Total Liabilities/EBITDA of 3.3 is comfortably below the Joseph Piotroski benchmark of <5.
+ Net profit margin has averaged 21.6% in the last 3 years. This is considered superior and suggests a high margin of safety.
+ As per the Du Pont analysis, Return on Equity is high at 42.3%.
Tobin's Q Ratio is 7.1. Compared with the rest of the market the stock is overvalued and ranks in the bottom 9% of stocks by value of Q Ratio.
The 0.6% discount to 12-month high of $A195.0 against the 64.9% premium to 12-month low of $A117.47 suggests the climb might be peaking.
Afternoon Alert: CSL increases 0.8%, leads S&P/ASX 200 Health Care index higher
June 20, 2018 13:00:00 AEST
CSL Limited (ASX:CSL) has increased 0.8% to trade at $A193.46 vs. the S&P/ASX 200 Health Care index which strengthened 221.4 points (or 0.7%) to 30,586.8. Representing a weighting of about 52.1% of the index, the stock accounted for 54.3% of today's gain. The shares have outperformed 87% of the market in the past three months.
Morning Alert: CSL decreases 0.03%, leads Pharmaceuticals & biotechnology sector lower
June 20, 2018 11:00:00 AEST
CSL Limited (ASX:CSL) has decreased 0.03% to trade at $A191.96 vs. the Pharmaceuticals & biotechnology sector which weakened 9.7 points (or 0.04%) to 23,177.6. Representing a weighting of about 89.8% of the sector, the stock accounted for 67.3% of today's loss.
CLOSING UPDATE: CSL lifts 2.9%, led S&P/ASX 200 Health Care index higher
June 19, 2018 16:00:00 AEST
CSL, Australia's largest pharmaceuticals & biotechnology company by market capitalisation, has lifted 2.9% to trade at $A192.01 vs. the S&P/ASX 200 Health Care index which strengthened 586.5 points (or 2%) to 30,365.4. Representing a weighting of about 52.2% of the index, the stock accounted for 76.8% of today's gain. The shares have outperformed 86% of the market in the past three months. Compared with the All Ordinaries Index which fell 4.0 points (or 0.06%) in the day, this represented a relative price increase of 3.0%.
Afternoon Alert: CSL lifts 3.3%, leads market higher
June 19, 2018 13:00:00 AEST
CSL Limited (ASX:CSL) has lifted 3.3% to trade at $A192.84 vs. the All Ordinaries Index which strengthened 22.4 points (or 0.4%) to 6,235.2. Representing a weighting of about 4.1% of the index, the stock accounted for 38.5% of today's gain. The shares have outperformed 85% of the market in the past three months.
CSL Limited (AU:CSL; ASX:CSL; AX:CSL)